drugset
Drugs / Monovalent [B.1.351] CoV2 preS dTM-AS03
last change Mar 2024 re-read 9 days ago

Monovalent [B.1.351] CoV2 preS dTM-AS03

also known as Sanofi-GSK COVID-19 Vaccine

Vaccine

Investigated by
Autoimmunity Centers of Excellence · National Institute of Allergy and Infectious Diseases (NIAID) · Rho Federal Systems Division, Inc.

Trials 1

today NCT05000216 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05000216 Aug 2021 → Jun 2023 juvenile dermatomyositis, juvenile idiopathic arthritis, pediatric multiple sclerosis, pediatric systemic lupus erythematosus +3 National Institute of Allergy and Infectious Diseases (NIAID) Terminated No outcome recorded Stop: Enrollment

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Monovalent [B.1.351] CoV2 preS dTM-AS03 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05000216 ↗
Known as Sanofi-GSK COVID-19 Vaccine “Sanofi-GSK COVID-19 Vaccine” NCT05000216 ↗
Modality Vaccine “Sanofi-GSK protein based COVID-19 vaccine” NCT05000216 ↗
Route Intramuscular “One dose administered intramuscularly” NCT05000216 ↗